ecteinascidin 743

ecteinascidin 743 Structure
CAS No.
114899-77-3
Chemical Name:
ecteinascidin 743
Synonyms
Trabectedin;ET-743;Yondelis;Ecteinascidin;NSC-684766;NSC 648766;ASMF Filed;cteinascidin;ecteinascidin 743;Trabectedin, >95%
CBNumber:
CB31364731
Molecular Formula:
C39H43N3O11S
Molecular Weight:
761.84
MOL File:
114899-77-3.mol
MSDS File:
SDS
Modify Date:
2024/8/28 13:53:22

ecteinascidin 743 Properties

Melting point >143°C (dec.)
alpha D25 +114° (c = 0.1 in methanol)
Density 1.55±0.1 g/cm3 (20 ºC 760 Torr)
storage temp. -20°C Freezer, Under inert atmosphere
solubility Chloroform (Slightly), Methanol (Slightly)
pka 9.73±0.40(Predicted)
form Solid
color Light Yellow to Yellow
optical activity -53.824.5 (CHCl3)
InChIKey PKVRCIRHQMSYJX-HAHYLZASNA-N

ecteinascidin 743 Chemical Properties,Uses,Production

Description

Trabectedin is a marine natural product derived from the tunicate Ecteinascidia turbinate. With its demonstrated in vitro and in vivo activity against a range of solid tumor cell lines, human xenografts and tumor explants, this antineoplastic agent has been developed and launched for the treatment of advanced STS after failure of first-line therapy with anthracyclines or ifosfamide or in patients who are unsuited to receive these agents. Its proposed mechanism of action involves binding to the N2 position of guanine in the minor groove demonstrating a preference for sequences containing 5′-PuGC and 5′-PyGG motifs. Subsequent alkylation of DNA, via an iminium intermediate generated from an intra-molecular acid-catalyzed activation and dehydration of the carbinolamine, induces a curvature of the DNA toward the major groove that ultimately disrupts the binding of transcription factors involved in cell proliferation. Evaluation of trabectedin against the National Cancer Institute’s human in vitro cell line panel, including melanoma, non-small-cell lung, ovarian, renal, prostate, and breast cancer, demonstrated potencies ranging from 1 pM to 10 nM.

Definition

ChEBI: A tetrahydroisoquinoline alkaloid obtained from a Caribbean tunicate Ecteinascidia turbinata. Used for the treatment of soft tissue sarcoma and relapsed ovarian cancer.

Side effects

The most common adverse events included nausea, fatigue, vomiting, anorexia, neutropenia, and increases in aspartate aminotransferase and alanine aminotransferase liver enzymes. To combat the nausea and vomiting, all patients must receive 20mg of dexamethasone intravenously before the trabectedin infusion. Not only does this pretreatment have an antiemetic effect, it also appears to offer a hepatoprotective benefit. Concomitant administration of potent inhibitors and inducers of CYP3A4 should be avoided since plasma levels of this CYP3A4- metabolized drug will be affected. Trabectedin is contraindicated in patients with a known hypersensitivity to trabectedin, concurrent serious or uncontrolled infection, or breast-feeding. Trabectedin should also not be administered in combination with yellow fever vaccine. Finally, there are strict criteria regarding absolute neutrophil count, platelet count, and renal and hepatic enzyme levels for permission to initiate or continue treatment with trabectedin.

ecteinascidin 743 Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 157)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
MSN LABORATORIES PRIVATE LTD +91 40 30438600 New Delhi, India 230 58 Inquiry
SynZeal Research Pvt Ltd +1 226-802-2078 Gujarat, India 6522 58 Inquiry
Pharmaffiliates Analytics and Synthetics P. Ltd +91-172-5066494 Haryana, India 6773 58 Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6351 58 Inquiry
AFINE CHEMICALS LIMITED +86-0571-85134551 China 15395 58 Inquiry
ChemExpress +86-021-58950125 +86-021-58950125; China 598 58 Inquiry
Hebei Yanxi Chemical Co., Ltd. +86-17531190177; +8617531190177 China 5873 58 Inquiry
Hangzhou FandaChem Co.,Ltd. 008657128800458; +8615858145714 China 9337 55 Inquiry
ATK CHEMICAL COMPANY LIMITED +undefined-21-51877795 China 32836 60 Inquiry
career henan chemical co +86-0371-86658258 +8613203830695 China 29888 58 Inquiry
ecteinascidin 743 (1'R,6R,6aR,7R,13S,14S,16R)- Trabectedin(Ecteinascidin 743,NSC-684766,ET-743, Yondelis) Ecteinascidine 743 NSC 648766 Trabectedin(Ecteinascidin 743,NSC-684766,ET-743) Trabectedin Ecteinascidin Yondelis R ,Trabectedin NSC-684766 Trabectedin (Ecteinascidin 743) PKVRCIRHQMSYJX-ZKZLGIKISA-N cteinascidin ECTEINASCIDIN 743; ET-743; ECTEINASCIDIN Trabectedin, >95% Trabectedin (Yondelis) Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinolin]-19-one, 5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (1'R,6R,6aR,7R,13S,14S,16R)- ASMF Filed TrabectedinQ: What is Trabectedin Q: What is the CAS Number of Trabectedin Q: What is the storage condition of Trabectedin Q: What are the applications of Trabectedin Trabectedin ET-743 Yondelis Ecteinascidin ecteinascidin 743,Trabectedin,ET 743 ET 743,Ecteinascidin743,inhibit,ROS,Inhibitor,Trabectedin,backbone,Ecteinascidin-743,Cytotoxicity,tetrahydroisoquinoline,superoxides,ET743,DNA,Apoptosis,alkaloid,cell-cycle,anti-inflammatory,antitumor,Reactive Oxygen Species (1′R,6R,6aR,7R,13S,14S,16R)-5-(Acetyloxy)-3′,4′,6,6a,7,13,14,16-octahydro-6′,8,14-trihydroxy-7′,9-dimethoxy-4,10,23-trimethylspiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1′(2′H)-isoquinolin]-19-one 114899-77-3 C39H43N3O11S Amines Heterocycles Intermediates & Fine Chemicals Pharmaceuticals API 114899-77-3